eltrombopag
Revolade · ATC code B02BX05
Brand names: Revolade, Elrevolan, Eltrombopag +pharma, Eltrombopag Devatis, Eltrombopag Krka, Eltrombopag Ratiopharm, Eltrombopag Reddy, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Viatris Pharma, Etrang, Geltro, Revopag, Rompag, Trotrag
- Key facts
- Active substance
- eltrombopag
- ATC code
- B02BX05
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Revolade 12.5 mg film-coated tablets / Revolade 25 mg film-coated tablets / Revolade 50 mg film-coated tablets · Revolade 25 mg powder for oral suspension
- Marketing authorisation holder
- Novartis Europharm Limited
- Information as of
- 2026-10-27
Key facts
Eltrombopag is an oral thrombopoietin receptor agonist that increases platelet production. It is used in refractory immune thrombocytopenia, thrombocytopenia in chronic hepatitis C and severe aplastic anaemia.
What it is used for
- Primary immune thrombocytopenia (ITP) in adults refractory to other treatments
- Primary ITP in children aged 1 year and above lasting 6 months or longer and refractory to other treatments
- Thrombocytopenia in adults with chronic hepatitis C when it prevents or limits interferon-based therapy
- Acquired severe aplastic anaemia in adults refractory to immunosuppressive therapy and unsuitable for stem cell transplantation
Dosing
- ITP, adults and children 6 to 17 years: starting dose 50 mg once daily; 25 mg for patients of East-/Southeast-Asian ancestry
- ITP, children 1 to 5 years: starting dose 25 mg once daily
- ITP: lowest dose achieving platelets ≥50 000/µl; do not exceed 75 mg daily; not intended to normalise counts
- Take at least two hours before or four hours after products with polyvalent cations (e.g. antacids, dairy, mineral supplements)
- The powder for oral suspension may give higher exposure than tablets; HCV and aplastic anaemia dosing in the full text
Contraindications
- Hypersensitivity to eltrombopag or any excipient
Important warnings
- HCV patients with advanced chronic liver disease: increased risk of potentially fatal hepatic decompensation and thromboembolic events
- Hepatotoxicity: increases in ALT, AST and bilirubin; monitor liver tests
- Thrombotic/thromboembolic events
- When switching between tablets and suspension, monitor platelet counts weekly
Side effects
- Most common in ITP: nausea, diarrhoea, increased ALT and back pain
- Most important serious reactions: hepatotoxicity and thrombotic/thromboembolic events
Interactions
- Statins (e.g. rosuvastatin): increased statin exposure; consider a reduced statin dose and monitoring
- OATP1B1 and BCRP substrates (e.g. methotrexate, topotecan): caution
- Polyvalent cations (iron, calcium, magnesium and others) reduce absorption
Pregnancy and breastfeeding
- Not recommended during pregnancy or in women of childbearing potential not using contraception
- Breast-feeding: weigh the benefit of breast-feeding against the benefit of therapy
Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- Eltrombopag Accord · genericAccord Healthcare S.L.U. · EMEA/H/C/006459
- Eltrombopag Viatris · genericViatris Limited · EMEA/H/C/006417
- RevoladeNovartis Europharm Limited · EMEA/H/C/001110
Source: European Medicines Agency (EMA), product information
Austria
- ElrevolanG.L. Pharma Gmbh · 1 register entry
- Eltrombopag +pharma+pharma Arzneimittel Gmbh · 1 register entry
- Eltrombopag DevatisDevatis Gmbh · 1 register entry
- Eltrombopag KrkaKrka, D.D., Novo Mesto · 1 register entry
- Eltrombopag RatiopharmRatiopharm Arzneimittel Vertriebs-Gmbh · 1 register entry
- Eltrombopag ReddyReddy Holding Gmbh · 1 register entry
- Eltrombopag SandozSandoz Gmbh · 1 register entry
- Eltrombopag StadaStada Arzneimittel Gmbh · 1 register entry
- Eltrombopag Viatris PharmaViatris Limited · 1 register entry
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Germany
- Eltrombopag1 A Pharma Gmbh, Ratiopharm Gmbh, Devatis Gmbh, Heumann Pharma Gmbh & Co. Generica Kg, Onkovis Gmbh, Vivanta Generics S.R.O., Amarox Pharma Gmbh, Cipla Europe Nv, Elpen Pharmaceutical Co. Inc., Olpha As, Stadapharm Gmbh, Abdi Farma Gmbh, Betapharm Arzneimittel Gmbh, Abz-Pharma Gmbh, Tad Pharma Gmbh, Aliud Pharma Gmbh · 16 register entries
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Turkey
- EtrangEİP ECZACIBAŞI İLAÇ PAZARLAMA A.Ş · 4 register entries
- GeltroNOBEL İLAÇ SAN. VE TİC. A.Ş. · 5 register entries
- RevoladeNOVARTİS SAĞLIK GIDA VE TARIM ÜRÜNLERİ SAN. VE TİC. A.Ş. · 3 register entries
- RevopagDEVA HOLDİNG A.Ş. · 7 register entries
- RompagABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş. · 6 register entries
- TrotragBİOFARMA İLAÇ SAN. VE TİC. A.Ş. · 4 register entries
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16
Brand names in 27 more European countries
- Belgium
- Eltrombopag Krka
- Bulgaria
- Eltrombopag Pharmascience, Eltrombopag Pharmdedict, Гелтро, Елтромбопаг Msn, Елтромбопаг Сандоз, Елтромбопаг Фармасайънс, Елтромбопаг Фармдедикт, Елтромбопаг Чайкафарма, Тосиета
- Croatia
- Eltrombopag Alpha-Medical, Eltrombopag Msn, Eltrombopag Pharmascience, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Teva, Eltrombopag Viatris Pharma, Mylatabi, Tocieta
- Cyprus
- Eltrombopag Msn, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Teva, Kadderum, Pageltra
- Czechia
- Eltrombopag Abdi, Eltrombopag Krka, Eltrombopag Msn, Eltrombopag Olpha, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Viatris Pharma, Eltrombopag Vipharm, Eltrombopag Vivanta, Mylatabi, Tocieta
- Denmark
- Eltrombopag Glenmark, Eltrombopag Krka, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Teva, Eltrombopag Viatris Pharma, Eltrombopag Vipharm, Eltrombopag Vivanta, Mylatabi
- Estonia
- Eltrombopag Krka, Eltrombopag Msn, Eltrombopag Olpha, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Teva, Eltrombopag Viatris Pharma
- Finland
- Eltrombopag Avansor, Eltrombopag Krka, Eltrombopag Sandoz, Eltrombopag Stada Stada, Eltrombopag Vivanta, Mylatabi
- France
- Eltrombopag Biogaran, Eltrombopag Eg, Eltrombopag Eloa Pharma, Eltrombopag Evolugen, Eltrombopag Krka, Eltrombopag Olpha, Eltrombopag Sandoz, Eltrombopag Teva, Eltrombopag Viatris Sante, Eltrombopag Vivanta
- Greece
- Eltrombopag Anabiosis, Eltrombopag Faran, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Teva, Eltrombopag Win Medica, Eltrombopag/Uni-Pharma, Emolado, Kadderum, Pageltra, Relatrom
- Hungary
- Elrevolan, Eltrombopag Elpen, Eltrombopag Krka, Eltrombopag Onkogen, Eltrombopag Pharmascience, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Vipharm, Pageltra, Tocieta
- Iceland
- Eltrombopag Accord, Eltrombopag Coripharma, Eltrombopag Krka, Eltrombopag Stada, Eltrombopag Viatris, Eltrombopag Wh, Mylatabi, Revolade, Yelmata
- Ireland
- Eltrombopag Clonmel, Eltrombopag Krka, Eltrombopag Msn, Eltrombopag Rowex, Eltrombopag Teva, Mylatabi
- Italy
- Elrevolan, Eltrombopag Abdi, Eltrombopag Cipla, Eltrombopag Dr. Reddy’s, Eltrombopag Eg, Eltrombopag Ever Pharma, Eltrombopag Glenmark, Eltrombopag Krka, Eltrombopag Medac, Eltrombopag Olpha, Eltrombopag Teva, Eltrombopag Vivanta
- Latvia
- Eltrombopag Krka, Eltrombopag Olpha, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Teva
- Liechtenstein
- Eltrombopag Accord, Eltrombopag Viatris, Revolade
- Lithuania
- Eltrombopag Krka, Eltrombopag Msn, Eltrombopag Olpha, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Viatris Pharma
- Malta
- Eltrombopag Aspen, Eltrombopag Clonmel, Eltrombopag Msn
- Netherlands
- Eltrombopag Abdi, Eltrombopag Amarox, Eltrombopag Aurobindo, Eltrombopag Devatis, Eltrombopag Glenmark, Eltrombopag Krka, Eltrombopag Mylan, Eltrombopag Olpha, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Synthon, Eltrombopag Teva, Eltrombopag Vivanta, Eltrombopag Will Pharma, Emolado, Mylatabi, Relatrom Rafarm, Tocieta
- Norway
- Eltrombopag Accord, Eltrombopag Glenmark, Eltrombopag Krka, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Teva, Eltrombopag Viatris, Eltrombopag Vivanta, Mylatabi, Revolade
- Poland
- Eltrombopag Glenmark, Eltrombopag Krka, Eltrombopag Msn, Eltrombopag Olpha, Eltrombopag Polpharma, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Tzf, Eltrombopag Viatris Pharma, Eltrombopag Vipharm
- Portugal
- Eltrombopag Bluepharma, Eltrombopag Cipla, Eltrombopag Krka, Eltrombopag Pharmconsul, Eltrombopag Reig Jofre, Eltrombopag Teva, Eltrombopag Viatris Pharma, Mylatabi
- Romania
- Eltrombopag Dr. Reddy’s, Eltrombopag Galenika, Eltrombopag Msn, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Teva, Tocieta
- Slovakia
- Eltrombopag Glenmark, Eltrombopag Krka, Eltrombopag Msn, Eltrombopag Olpha, Eltrombopag Pharmevid, Eltrombopag Stada, Eltrombopag Vipharm, Tocieta
- Slovenia
- Eltrombopag Krka, Eltrombopag Msn, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Teva
- Spain
- Eltrombgopa Glenmark, Eltrombopag Aurovitas Spain, Eltrombopag Cipla, Eltrombopag Combix, Eltrombopag Dr.Reddys, Eltrombopag Glenmark, Eltrombopag Kern Pharma, Eltrombopag Olpha, Eltrombopag Sala, Eltrombopag Sandoz, Eltrombopag Stada, Eltrombopag Tarbis, Eltrombopag Vivanta
- Sweden
- Eltrombopag Anabiosis, Eltrombopag Avansor, Eltrombopag Bioglan, Eltrombopag Glenmark, Eltrombopag Krka, Eltrombopag Reddy, Eltrombopag Sandoz, Eltrombopag Stada Stada, Eltrombopag Teva, Eltrombopag Vivanta, Kadderum, Lomvesmi, Mylatabi
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Revolade – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/revolade-epar-product-information_en.pdf
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.